Ask AI
ASCO 2025 GU

CE / CME

ASCO 2025 Conference to Clinic: Genitourinary Cancers

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Released: July 01, 2025

Expiration: December 31, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

In the phase III NIAGARA study of muscle-invasive bladder cancer, which of the following patient populations defined by preradical cystectomy circulating tumor DNA (ctDNA) status was highly correlated with nonpathologic complete response?

2.

When counseling patients with metastatic urothelial carcinoma about treatment with enfortumab vedotin with pembrolizumab, what would you tell them is the probability of maintaining complete response at 24 months?

3.

What was a key 5-year follow-up finding of the phase III ARCHES trial of enzalutamide with androgen-deprivation therapy (ADT) vs placebo with ADT for patients with metastatic hormone-sensitive prostate cancer?